October 13, 2021

Now available OPDIVO®

On August 19, 2021, the Food and Drug Administration approved OPDIVO (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.

View full prescribing information and all indications.